Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.

Clin Transl Gastroenterol · 2021 · PMC7886452 · PMID 33735154

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

almost significantlyP = 0.056so close (0.05 < p ≤ 0.1)

At 3 years of follow-up, predicted response using our assay was independently and almost significantly associated with the need to discontinue IFX ( P = 0.056), whereas statistical significance was not reached for the years 4 and 5.

also in 555 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.